Cytek Biosciences Inc
NASDAQ:CTKB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cytek Biosciences Inc
Capital Expenditures
Cytek Biosciences Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
Capital Expenditures
-$4.2m
|
CAGR 3-Years
25%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Capital Expenditures
-$1.5B
|
CAGR 3-Years
12%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-14%
|
|
|
Danaher Corp
NYSE:DHR
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Waters Corp
NYSE:WAT
|
Capital Expenditures
-$112.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-1%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Capital Expenditures
-$403m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-15%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Capital Expenditures
-$603m
|
CAGR 3-Years
4%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-23%
|
|
Cytek Biosciences Inc
Glance View
Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. The company is headquartered in Fremont, California and currently employs 496 full-time employees. The company went IPO on 2021-07-23. The firm offers cell analysis tools by leveraging technical approaches. Its instruments, the Aurora and Northern Lights systems, are the spectrum flow cytometers able to deliver cell analysis by utilizing the spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells Full Spectrum Profiling (FSP). The Company’s FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize a method of light detection and distribution. Its FSP platform includes instruments, reagents, software and services to provide an integrated suite of solutions for its customers. The firm has sold and deployed over 1,000 instruments, primarily comprised of its Aurora and Northern Lights systems to customers around the world, including the pharmaceutical companies, over 150 biopharma companies, academic research centers, and clinical research organizations (CROs).
See Also
What is Cytek Biosciences Inc's Capital Expenditures?
Capital Expenditures
-4.2m
USD
Based on the financial report for Dec 31, 2025, Cytek Biosciences Inc's Capital Expenditures amounts to -4.2m USD.
What is Cytek Biosciences Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-22%
Over the last year, the Capital Expenditures growth was -12%. The average annual Capital Expenditures growth rates for Cytek Biosciences Inc have been 25% over the past three years , -22% over the past five years .